TRMT61B: A Drug Target or Biomarker for Mitochondrial Function

Target Name: TRMT61B

NCBI ID: G55006

TRMT61B

Other Name(s): TRNA (adenine(58)-N(1))-methyltransferase, mitochondrial | potential tRNA (adenine-N(1)-)-methyltransferase catalytic subunit TRMT61B | tRNA methyltransferase 61 homolog B | tRNA (adenine(58)-N(1))-methyltransferase, mitochondrial | TRNA methyltransferase 61B | TR61B_HUMAN | potential tRNA (adenine(58)-N(1))-methyltransferase catalytic subunit TRMT61B | mRNA methyladenosine-N(1)-methyltransferase | tRNA methyltransferase 61B | Potential tRNA (adenine(58)-N(1))-methyltransferase catalytic subunit TRMT61B | Potential tRNA (adenine-N(1)-)-methyltransferase catalytic subunit TRMT61B

TRMT61B: A Drug Target or Biomarker for Mitochondrial Function

Mitochondria are organelles responsible for generating energy in the form of ATP in cells of the human body. They are also involved in the production of various molecules, including proteins, neurotransmitters, and energy-carrying molecules. One of the key enzymes involved in these processes is TRMT61B, which is a mitochondrial enzyme that adds a methyl group to specific amino acids, including adenine.

TRMT61B is a crucial enzyme for the proper functioning of the mitochondria, and its dysfunction has been linked to a number of diseases, including Alzheimer's, Parkinson's, and Huntington's diseases. It is also a potential drug target for a variety of conditions. In this article, we will explore the function of TRMT61B and its potential as a drug target.

Function of TRMT61B

TRMT61B is a mitochondrial enzyme that catalyzes the transfer of a methyl group from adenine to specific amino acids, such as lysine and arginine. This process involves a series of steps, including the formation of a S-adenosylmethionine (SAM) molecule, which is then reduced to its active form by the addition of the methyl group.

The primary function of TRMT61B is to modulate the levels of methyl groups on specific amino acids, such as adenine, in the brain and other tissues. This is important for the regulation of various cellular processes, including protein synthesis, neurotransmitter synthesis, and cellular signaling pathways. Methylation of these amino acids can also play a role in the development and progression of certain diseases, such as Alzheimer's and Parkinson's diseases.

TRMT61B is also involved in the production of other important molecules in the brain, including the neurotransmitter serotonin. In addition, it is involved in the regulation of cellular processes that are critical for brain development and function, such as the production of new neurons and the regulation of neurotransmitter release.

Potential Drug Target

TRMT61B is a potential drug target for a variety of conditions, including neurological and psychiatric disorders. Its dysfunction has been linked to the development of a number of these conditions, including Alzheimer's and Parkinson's diseases. By targeting TRMT61B, researchers may be able to develop new treatments for these conditions.

One approach to targeting TRMT61B is to use small molecules that can modulate its activity. These molecules can be designed to interact with specific TRMT61B enzymes to alter their catalytic activity or stability. One example of a small molecule that has been shown to interact with TRMT61B is 3-[(2-methylphenyl) amin]-1-propanone (3-MePA), which has been shown to inhibit the activity of TRMT61B and decrease the levels of methyl groups on specific amino acids in the brain.

Another approach to targeting TRMT61B is to use drugs that can modulate its expression or function. For example, researchers have used RNA interference techniques to knock down the expression of TRMT61B in neurons and to confirm that this has the effect of reducing the levels of methyl groups on these neurons. They have also used small molecules to alter the stability of TRMT61B, leading to increased levels of this enzyme in the brain.

Conclusion

In conclusion, TRMT61B is a crucial enzyme involved in the regulation of various cellular processes in the brain. Its dysfunction has been linked to the development of a number of neurological and psychiatric disorders, including Alzheimer's and Parkinson's diseases. As a potential drug target, TRMT61B is an attractive target for the development of new treatments for these disorders. The use of small molecules that can modulate its activity or expression may lead to new treatments for

Protein Name: TRNA Methyltransferase 61B

Functions: Methyltransferase that catalyzes the formation of N(1)-methyladenine at position 58 (m1A58) in various tRNAs in mitochondrion, including tRNA(Leu) (deciphering codons UUA or UUG), tRNA(Lys) and tRNA(Ser) (deciphering codons UCA, UCU, UCG or UCC) (PubMed:23097428). Catalyzes the formation of 1-methyladenosine at position 947 of mitochondrial 16S ribosomal RNA and this modification is most likely important for mitoribosomal structure and function (PubMed:27631568). In addition to tRNA N(1)-methyltransferase activity, also acts as a mRNA N(1)-methyltransferase by mediating methylation of adenosine residues at the N(1) position of MT-ND5 mRNA, leading to interfere with mitochondrial translation (PubMed:29107537)

The "TRMT61B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRMT61B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets